Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study [Cancer-Related Complications]
Purpose Cognitive dysfunction is reported in people with cancer. Therefore, we evaluated longitudinal changes in cognitive function and underlying mechanisms in people with colorectal cancer (CRC) and healthy controls (HCs). Patients and Methods Participants completed cognitive assessments and questionnaires reporting cognitive symptoms, fatigue, quality of life, and anxiety/depression at baseline (before chemotherapy, if given) and 6, 12, and 24 months. Blood tests included cytokines, clotting factors, apolipoprotein E genotype, and sex hormones. Primary end point was overall cognitive function measured by the Global Def...
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Vardy, Dhillon, Pond, Rourke, Bekele, Renton, Dodd, Zhang, Beale, Clarke, Tannock Tags: Supportive Care, Chemotherapy, Quality of Life, Supportive Care Cancer-Related Complications Source Type: research

Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial [Melanoma]
Purpose To evaluate the efficacy, safety, tolerability, and quality of life (QoL) in patients receiving intravenous, intermittent high-dose interferon alfa-2b (IFN-α-2b [iHDI]) compared with standard high-dose IFN-α-2b (HDI). Patient and Methods Patients with stage III resected lymph node or in-transit metastasis from cutaneous malignant melanoma were randomly assigned to receive either a standard HDI regimen or three courses of IFN-α-2b 20 MIU/m2 administered intravenously 5 days a week for 4 weeks then repeated every 4 months. Distant metastasis-free survival was the primary end point for efficacy anal...
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Mohr, Hauschild, Trefzer, Enk, Tilgen, Loquai, Gogas, Haalck, Koller, Dummer, Gutzmer, Brockmeyer, Holzle, Sunderkotter, Mauch, Stein, Schneider, Podda, Goppner, Schadendorf, Weichenthal Tags: Combined Modality Melanoma Source Type: research

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697) [Melanoma]
Conclusion Neither adjuvant GM-CSF nor PV significantly improved RFS or OS in patients with high-risk resected melanoma. Exploratory analyses suggest that GM-CSF may be beneficial in patients with resected visceral metastases; this observation requires prospective validation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Lawson, Lee, Zhao, Tarhini, Margolin, Ernstoff, Atkins, Cohen, Whiteside, Butterfield, Kirkwood Tags: Chemotherapy Melanoma Source Type: research

Female Estrogen-Related Factors and Incidence of Basal Cell Carcinoma in a Nationwide US Cohort [Cancer Prevention and Control]
Conclusion These analyses confirm a previous finding of increased risk of BCC associated with MHT. Novel findings of increased BCC risk associated with MHT in women experiencing natural menopause and for late age at natural menopause warrant further investigation. Users of MHT may constitute an additional high-risk group in need of more frequent skin cancer screening. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Cahoon, Kitahara, Ntowe, Bowen, Doody, Alexander, Lee, Little, Linet, Freedman Tags: Non-Melanoma Skin Cancer Cancer Prevention and Control Source Type: research

Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods [Clinical Trials]
Conclusion The absolute and relative change metrics are not meaningfully better than RECIST in predicting OS. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: An, Han, Meyers, Bogaerts, Sargent, Mandrekar Tags: Clinical Trials Source Type: research

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed [Gastrointestinal Cancer]
Conclusion Ruxolitinib plus capecitabine was generally well tolerated and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Hurwitz, Uppal, Wagner, Bendell, Beck, Wade, Nemunaitis, Stella, Pipas, Wainberg, Manges, Garrett, Hunter, Clark, Leopold, Sandor, Levy Tags: Combined Modality Gastrointestinal Cancer Source Type: research

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer [Gastrointestinal Cancer]
Conclusion In marked contrast to the results seen in patients with BRAF V600E–mutant melanoma, single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC. Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Kopetz, Desai, Chan, Hecht, O'Dwyer, Maru, Morris, Janku, Dasari, Chung, Issa, Gibbs, James, Powis, Nolop, Bhattacharya, Saltz Tags: Chemotherapy, Translational Oncology Gastrointestinal Cancer Source Type: research

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer [Gastrointestinal Cancer]
Conclusion The combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600–mutant mCRC. Mitogen-activated protein kinase signaling was inhibited in all patients evaluated, but to a lesser degree than observed in BRAF-mutant melanoma with dabrafenib alone. PIK3CA mutations were identified in responding patients and thus do not preclude response to this regimen. Additional studies targeting the mitogen-activated protein kinase pathway in this disease are warranted. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Corcoran, Atreya, Falchook, Kwak, Ryan, Bendell, Hamid, Messersmith, Daud, Kurzrock, Pierobon, Sun, Cunningham, Little, Orford, Motwani, Bai, Patel, Venook, Kopetz Tags: Chemotherapy, Translational Oncology Gastrointestinal Cancer Source Type: research

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer [Gynecologic Cancer]
Conclusion This study, to our knowledge, is the first to explore the effects of nivolumab against ovarian cancer. The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714). (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Hamanishi, Mandai, Ikeda, Minami, Kawaguchi, Murayama, Kanai, Mori, Matsumoto, Chikuma, Matsumura, Abiko, Baba, Yamaguchi, Ueda, Hosoe, Morita, Yokode, Shimizu, Honjo, Konishi Tags: Translational Oncology, Gynecologic Gynecologic Cancer Source Type: research

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial [Thoracic Oncology]
Conclusion Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Kelly, Altorki, Eberhardt, O'Brien, Spigel, Crino, Tsai, Kim, Cho, Hoffman, Orlov, Serwatowski, Wang, Foley, Horan, Shepherd Tags: Surgery, Chemotherapy Thoracic Oncology Source Type: research

Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial [Hematologic Malignancy]
Conclusion For recipients of alloHSCT, compared with G-CSF, prophylactic GM-CSF was associated with lower 100-day transplantation-related mortality, lower 100-day cumulative mortality, and lower 600-day IFD-related mortality. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Wan, Zhang, Lai, Jiang, Song, Zhou, Zhang, Duan, Fu, Liao, Wang Tags: Leukemia, Lymphoma Hematologic Malignancy Source Type: research

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study [Hematologic Malignancy]
Conclusion DLBCL relapse after first CR is infrequent, and the widespread use of routine imaging in Denmark did not translate into better survival. This favors follow-up without routine imaging and, more generally, a shift of focus from relapse detection to improved survivorship. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: El-Galaly, Jakobsen, Hutchings, de Nully Brown, Nilsson-Ehle, Szekely, Mylam, Hjalmar, Johnsen, Bogsted, Jerkeman Tags: Epidemiology, Diagnosis & Staging, Nuclear Medicine, CT Hematologic Malignancy Source Type: research

Hitting the Target in BRAF-Mutant Colorectal Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Nagaraja, Bass Tags: Phase I and Clinical Pharmacology, Translational Oncology, Signal Transduction, Gastrointestinal EDITORIALS Source Type: research

Targeting Programmed Cell Death 1 in Ovarian Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Homicsko, Coukos Tags: Phase I and Clinical Pharmacology, Chemotherapy, Translational Oncology, Cancer Biomarkers, Immunology/Immunobiology, Phase I and Clinical Pharmacology EDITORIALS Source Type: research

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Novello Tags: Surgery, Combined Modality EDITORIALS Source Type: research

To Surveil or Not to Surveil [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Armitage, Vose Tags: Radiation EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Muscular Relapse in a Patient With Multiple Myeloma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Waheed, Zhu, Waheed, Kumar, Barlogie Tags: Diagnosis & Staging, Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: research

ERRATUM [Errata]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Errata Source Type: research

US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Kim, Lurie, Pazdur Tags: CORRESPONDENCE Source Type: research

Reply to L. Antolini et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Mittendorf, Bedrosian, Hunt Tags: CORRESPONDENCE Source Type: research

Lymph Node Micrometastases Do Influence Breast Cancer Outcome [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Antolini, Biganzoli, Querzoli, Piantelli, Alberti Tags: CORRESPONDENCE Source Type: research

Reply to R. Warsame et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Bochtler, Hegenbart, Kunz, Benner, Schonland Tags: CORRESPONDENCE Source Type: research

Blaming the Right Fluorescent in Situ Hybridization [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Warsame, Dispenzieri Tags: CORRESPONDENCE Source Type: research

Reply to L. Wiener et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Eaton Russell, Bouffet Tags: CORRESPONDENCE Source Type: research

Deeper Conversations Need Not Wait Until the End [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Wiener, Feudtner, Hinds, Wolfe, Mack Tags: CORRESPONDENCE Source Type: research

A Drop of Blood [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Karp Leaf Tags: End of life issues, Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Biomarker: Predictive or Prognostic? [STATISTICS IN BRIEF]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Ballman Tags: Statistics in Oncology STATISTICS IN BRIEF Source Type: research

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement [ASCO SPECIAL ARTICLES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Ligibel, Alfano, Hershman, Ballard, Bruinooge, Courneya, Daniels, Demark-Wahnefried, Frank, Goodwin, Irwin, Levit, McCaskill-Stevens, Minasian, O'Rourke, Pierce, Stein, Thomson, Hudis Tags: Policy Analysis, Quality of Care ASCO SPECIAL ARTICLES Source Type: research

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F [REVIEW ARTICLES]
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A decade after the seminal discovery of an activating mutation in the tyrosine kinase JAK2 in nearly all patients with PV, new treatment options are finally beginning to emerge, necessitating a critical reappraisal of the underlying pathogenesis and therapeutic modalities available for PV. Herein, we comprehensively review clinical aspects of PV including diagnostic considerations, natural history, and risk factors for thrombosis. We summarize recent ...
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Stein, Oh, Berenzon, Hobbs, Kremyanskaya, Rampal, Abboud, Adler, Heaney, Jabbour, Komrokji, Moliterno, Ritchie, Rice, Mascarenhas, Hoffman Tags: Epidemiology, Diagnosis & Staging, Biological Therapy, Biology & Immunology REVIEW ARTICLES Source Type: research

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk [Breast Cancer]
Purpose The increased breast cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood. Here, we review our 29-year longitudinal experience with LCIS to evaluate factors associated with breast cancer risk. Patients and Methods Patients participating in surveillance after an LCIS diagnosis are observed in a prospectively maintained database. Comparisons were made among women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009. Results One thousand sixty patients with LCIS without concurrent breast cancer ...
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: King, Pilewskie, Muhsen, Patil, Mautner, Park, Oskar, Guerini-Rocco, Boafo, Gooch, De Brot, Reis-Filho, Morrogh, Andrade, Sakr, Morrow Tags: Diagnosis & Staging, Surgery, Chemotherapy Breast Cancer Source Type: research

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study [Breast Cancer]
Conclusion For patients with DCIS selected for favorable clinical and pathologic characteristics and treated with excision without radiation, the risks of developing an IBE and an invasive IBE increased through 12 years of follow-up, without plateau. These data help inform the treatment decision-making process for patients and their physicians. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Solin, Gray, Hughes, Wood, Lowen, Badve, Baehner, Ingle, Perez, Recht, Sparano, Davidson Tags: Surgery, Radiation Breast Cancer Source Type: research

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy [Hematologic Malignancy]
Conclusion Our study provides encouraging evidence for associations between loci at 5q23.2 and 6q21 with EFS and OS in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, suggesting novel biology and the potential contribution of host genetics to the prognosis of this aggressive malignancy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Ghesquieres, Slager, Jardin, Veron, Asmann, Maurer, Fest, Habermann, Bene, Novak, Mareschal, Haioun, Lamy, Ansell, Tilly, Witzig, Weiner, Feldman, Dogan, Cunningham, Olswold, Molina, Link, Milpied, Cox, Salles, Cerhan Tags: Epidemiology Hematologic Malignancy Source Type: research

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens [Hematologic Malignancy]
Conclusion Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Niesvizky, Flinn, Rifkin, Gabrail, Charu, Clowney, Essell, Gaffar, Warr, Neuwirth, Zhu, Elliott, Esseltine, Niculescu, Reeves Tags: Geriatric Oncology, Translational Oncology Hematologic Malignancy Source Type: research

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma [Hematologic Malignancy]
Conclusion We have refined our understanding of genetic events in myeloma and identified clinically relevant mutations that may be used to better stratify patients at presentation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Walker, Boyle, Wardell, Murison, Begum, Dahir, Proszek, Johnson, Kaiser, Melchor, Aronson, Scales, Pawlyn, Mirabella, Jones, Brioli, Mikulasova, Cairns, Gregory, Quartilho, Drayson, Russell, Cook, Jackson, Leleu, Davies, Morgan Tags: Diagnosis & Staging, Biology & Immunology Hematologic Malignancy Source Type: research

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial [Hematologic Malignancy]
Conclusion The combination of high doses of antimetabolites, R-HDS, and ASCT is feasible and effective in patients age 18 to 70 years old with secondary CNS lymphoma, and we propose it as a new standard therapeutic option. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Ferreri, Donadoni, Cabras, Patti, Mian, Zambello, Tarella, Di Nicola, D'Arco, Doa, Bruno-Ventre, Assanelli, Foppoli, Citterio, Fanni, Mule, Caligaris-Cappio, Ciceri Tags: Lymphoma, Chemotherapy Hematologic Malignancy Source Type: research

Computerized Cognitive Training for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors: A Randomized Controlled Trial [Pediatric Oncology]
Conclusion Study findings show computerized cognitive training is feasible and efficacious for childhood cancer survivors, with evidence for training-related neuroplasticity. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Conklin, Ogg, Ashford, Scoggins, Zou, Clark, Martin-Elbahesh, Hardy, Merchant, Jeha, Huang, Zhang Tags: Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, CNS Tumors Pediatric Oncology Source Type: research

Impact of Tailored Education on Awareness of Personal Risk for Therapy-Related Complications Among Childhood Cancer Survivors [Pediatric Oncology]
Purpose Survivors of childhood cancer carry a substantial burden of long-term morbidity; personal risk awareness is critical to ensure survivors' engagement in early detection/management of complications. The impact of education provided in survivorship clinics on survivors' understanding of their personal health risks is unclear. Methods Patients diagnosed with cancer at age 21 years or younger and at 2 or more years off therapy completed questionnaires about awareness of personal risk for therapy-related complications at T0 (first survivorship clinic visit) and at T1 to T5 (subsequent visits). After questionnaire comple...
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Landier, Chen, Namdar, Francisco, Wilson, Herrera, Armenian, Wolfson, Sun, Wong, Bhatia Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research

Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B [Thoracic Oncology]
Purpose We have investigated the potential of metabolomics to discover blood-based biomarkers relevant to lung cancer screening and early detection. An untargeted metabolomics approach was applied to identify biomarker candidates using prediagnostic sera from the Beta-Carotene and Retinol Efficacy Trial (CARET) study. Patients and Methods A liquid chromatography/mass spectrometry hydrophilic interaction method designed to profile a wide range of metabolites was applied to prediagnostic serum samples from CARET participants (current or former heavy smokers), consisting of 100 patients who subsequently developed non–s...
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Wikoff, Hanash, DeFelice, Miyamoto, Barnett, Zhao, Goodman, Feng, Gandara, Fiehn, Taguchi Tags: Diagnosis & Staging, Cancer Biomarkers, Lung Thoracic Oncology Source Type: research

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium [Gastrointestinal Cancer]
Conclusion mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for patients with metastatic gastric or GEJ adenocarcinoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Shah, Janjigian, Stoller, Shibata, Kemeny, Krishnamurthi, Su, Ocean, Capanu, Mehrotra, Ritch, Henderson, Kelsen Tags: Chemotherapy Gastrointestinal Cancer Source Type: research

Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option? [Gastrointestinal Cancer]
Conclusion The results of this large multicenter study from the modern era suggest that SALV can offer acceptable short- and long-term outcomes in selected patients at experienced centers. Persistent cancer after definitive chemoradiotherapy seems to be more biologically aggressive, with poorer survival compared with recurrent cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Markar, Gronnier, Duhamel, Pasquer, Thereaux, du Rieu, Lefevre, Turner, Luc, Mariette Tags: Surgery, Combined Modality Gastrointestinal Cancer Source Type: research

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [Gastrointestinal Cancer]
Conclusion Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATMlow patients. A phase III trial in this setting is under way. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Bang, Im, Lee, Cho, Song, Lee, Kim, Park, Chun, Zang, Fielding, Rowbottom, Hodgson, O'Connor, Yin, Kim Tags: Combined Modality, Translational Oncology Gastrointestinal Cancer Source Type: research

Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy [ONCOLOGY GRAND ROUNDS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Ku, Ilson Tags: Oncology Grand Rounds Source Type: research

Advances in the Treatment of Secondary CNS Lymphoma [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Schmitz, Wu Tags: Chemotherapy EDITORIALS Source Type: research

Enhancing Health Care of Survivors of Childhood Cancer With Tailored Education [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Henderson, Oeffinger Tags: Long Term Survival & Late Effects EDITORIALS Source Type: research

Screening for Lung Cancer: What Comes Next? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Peled, Ilouze Tags: EDITORIALS Source Type: research

Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Burtness Tags: Chemotherapy, Translational Oncology EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Johnson, Saranga-Perry, Lavin, Burnette, Clark, Uskavitch, Wallace, Dickson, Kudchadkar, Sosman Tags: Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: research